2016 Volume 17 Issue 3 Pages 159-162
We designed a de novo hepatitis B prevention system and did outcome evaluation of the system. We have been informing the attending physicians whenever HBV-DNA was positive to prevent de novo hepatitis B, and held lectures to inform on de novo hepatitis B. However, adherence rate to guideline of de novo hepatitis B was very low at 20.3%. We then inserted an on-screen alert system for de novo hepatitis B in our electronic medical recording system. Consequently, the adherence rate improved up to 34.2%. Next step, we put an alert sheet under clear cover of the medical records to examine HBsAb, HBcAb and HBV-DNA. Adherence rate to guideline markedly improved to 63.8%. After initiating this system, three cases were successfully treated before de novo hepatitis B break out, so we think this system is effective to prevent de novo hepatitis B to some extent. We will continue improving de novo hepatitis B prevention system to inform physicians before starting chemotherapy.
